{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:08:26Z","timestamp":1792062506198,"version":"4.4.0"},"reference-count":27,"publisher":"American Psychiatric Association Publishing","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AJP"],"published-print":{"date-parts":[[2005,6,1]]},"DOI":"10.1176\/appi.ajp.162.6.1142","type":"journal-article","created":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T14:49:27Z","timestamp":1117637367000},"page":"1142-1148","source":"Crossref","is-referenced-by-count":406,"title":["Risperidone for the Core Symptom Domains of Autism: Results From the Study by the Autism Network of the Research Units on Pediatric Psychopharmacology"],"prefix":"10.1176","volume":"162","author":[{"given":"Christopher J.","family":"McDougle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Scahill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Aman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"McCracken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Tierney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Eugene","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Posey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e8s","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaswinder K.","family":"Ghuman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavik","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley Z.","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi B.","family":"Swiezy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilda M.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Hollway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"McGough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Ritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetto","family":"Vitiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"230","reference":[{"key":"R1626BABJGIEA","doi-asserted-by":"crossref","unstructured":"Research Units on Pediatric Psychopharmacology Autism Network: Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002; 347:314\u2013321","DOI":"10.1056\/NEJM200212053472316"},{"key":"R1626BABBDJIF","doi-asserted-by":"crossref","unstructured":"McDougle CJ, Scahill L, McCracken JT, Aman MG, Tierney E, Arnold LE, Freeman BJ, Martin A, McGough JJ, Posey DJ, Riddle MA, Ritz L, Swiezy NB, Vitiello B, Volkmar FR, Votolato N, Walson P (Research Units on Pediatric Psychopharmacology [RUPP] Autism Network): Background and rationale for an initial controlled study of risperidone. Child Adolesc Psychiatr Clin N Am 2000; 9:201\u2013224","DOI":"10.1016\/S1056-4993(18)30142-1"},{"key":"R1626BABFBCDH","doi-asserted-by":"crossref","unstructured":"Arnold LE, Aman MG, Martin A, Collier-Crespin A, Vitiello B, Tierney E, Asarnow R, Bell-Bradshaw F, Freeman BJ, Gates-Ulanet P, Klin A, McCracken JT, McDougle CJ, McGough JJ, Posey DJ, Scahill L, Swiezy NB, Ritz L, Volkmar F: Assessment in multisite randomized clinical trials of patients with autistic disorder: the Autism RUPP Network. J Autism Dev Disord 2000; 30:99\u2013111","DOI":"10.1023\/A:1005451304303"},{"key":"R1626BABDGHCD","doi-asserted-by":"crossref","unstructured":"Scahill L, McCracken J, McDougle CJ, Aman M, Arnold LE, Tierney E, Cronin P, Davies M, Ghuman J, Gonzalez N, Koenig K, Lindsay R, Martin A, McGough J, Posey DJ, Swiezy N, Volkmar F, Ritz L, Vitiello B: Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism. J Child Adolesc Psychopharmacol 2001; 11:377\u2013388","DOI":"10.1089\/104454601317261555"},{"key":"R1626BABFIHCJ","doi-asserted-by":"crossref","unstructured":"Aman MG, Singh NN, Stewart AW, Field CJ: The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 1985; 89:485\u2013491","DOI":"10.1037\/t10453-000"},{"key":"R1626BABJIGCE","doi-asserted-by":"crossref","unstructured":"Freeman BJ, Ritvo ER, Yokota A, Ritvo A: A scale for rating symptoms of patients with the syndrome of autism in real life settings. J Am Acad Child Adolesc Psychiatry 1986; 25:130\u2013136","DOI":"10.1016\/S0002-7138(09)60610-5"},{"key":"R1626BABDEFAF","doi-asserted-by":"crossref","unstructured":"Scahill L, Riddle MA, McSwiggin-Hardin M, Ort SI, King RA, Goodman WK, Cicchetti D, Leckman JF: Children\u2019s Yale-Brown Obsessive Compulsive Scale: reliability and validity. J Am Acad Child Adolesc Psychiatry 1997; 36:844\u2013852","DOI":"10.1097\/00004583-199706000-00023"},{"key":"R1626BABJACHD","doi-asserted-by":"crossref","unstructured":"Arnold LE, Vitiello B, McDougle C, Scahill L, Shah B, Gonzalez NM, Chuang S, Davies M, Hollway J, Aman MG, Cronin P, Koenig K, Kohn AE, McMahon DJ, Tierney E: Parent-defined target symptoms respond to risperidone in RUPP Autism Study: customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry 2003; 42:1443\u20131450","DOI":"10.1097\/00004583-200312000-00011"},{"key":"R1626BABFHCIA","doi-asserted-by":"crossref","unstructured":"Lord C, Rutter M, Le Couteur A: Autism Diagnostic Interview\u2014Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 1994; 24:659\u2013685","DOI":"10.1007\/BF02172145"},{"key":"R1626BABEFACC","unstructured":"Ritvo ER, Freeman BJ, Yuwiler A, Geller E, Schroth P, Yokota A, Mason-Brothers A, August GJ, Klykylo W, Leventhal B, Lewis K, Piggott L, Realmuto G, Stubbs EG, Umansky R: Fenfluramine treatment of autism: UCLA collaborative study of 81 patients at nine medical centers. Psychopharmacol Bull 1986; 22:133\u2013140"},{"key":"R1626BABFEEAG","doi-asserted-by":"crossref","unstructured":"McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH: A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 1996; 53:1001\u20131008","DOI":"10.1001\/archpsyc.1996.01830110037005"},{"key":"R1626BABHGDBD","doi-asserted-by":"crossref","unstructured":"McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH: A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 1998; 55:633\u2013641","DOI":"10.1001\/archpsyc.55.7.633"},{"key":"R1626BABGJHAA","unstructured":"Sanchez LE, Adams PB, Uysal S, Hallin A, Campbell M, Small AM: A comparison of live and videotape ratings: clomipramine and haloperidol in autism. Psychopharmacol Bull 1995; 31:371\u2013378"},{"key":"R1626BABBFIJI","doi-asserted-by":"crossref","unstructured":"Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS: The Yale-Brown Obsessive Compulsive Scale, I: development, use, and reliability. Arch Gen Psychiatry 1989; 46:1006\u20131011","DOI":"10.1001\/archpsyc.1989.01810110048007"},{"key":"R1626BABIAFHG","doi-asserted-by":"crossref","unstructured":"Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS: The Yale-Brown Obsessive Compulsive Scale, II: validity. Arch Gen Psychiatry 1989; 46:1012\u20131016","DOI":"10.1001\/archpsyc.1989.01810110054008"},{"key":"R1626BABICJHC","doi-asserted-by":"crossref","unstructured":"McDougle CJ, Kresch LE, Goodman WK, Naylor ST, Volkmar FR, Cohen DJ, Price LH: A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder. Am J Psychiatry 1995; 152:772\u2013777","DOI":"10.1176\/ajp.152.5.772"},{"key":"R1626BABEDCGB","doi-asserted-by":"crossref","unstructured":"McDougle CJ, Holmes JP, Bronson MR, Anderson GM, Volkmar FR, Price LH, Cohen DJ: Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry 1997; 36:685\u2013693","DOI":"10.1097\/00004583-199705000-00020"},{"key":"R1626BABIIHCG","doi-asserted-by":"crossref","unstructured":"Gibbons RD, Hedeker D, Elkin I, Waternaux C, Kraemer HC, Greenhouse JB, Shea MT, Imber SD, Sotsky SM, Watkins JT: Some conceptual and statistical issues in analysis of longitudinal psychiatric data: application to the NIMH Treatment of Depression Collaborative Research Program dataset. Arch Gen Psychiatry 1993; 50:739\u2013750","DOI":"10.1001\/archpsyc.1993.01820210073009"},{"key":"R1626BABCCFAI","doi-asserted-by":"crossref","unstructured":"Constantino JN, Davis SA, Todd RD, Schindler MK, Gross MM, Brophy SL, Metzger LM, Shoushtari CS, Splinter R, Reich W: Validation of a brief quantitative measure of autistic traits: comparison of the Social Responsiveness Scale with the Autism Diagnostic Interview\u2014Revised. J Autism Dev Disord 2003; 33:427\u2013433","DOI":"10.1023\/A:1025014929212"},{"key":"R1626BABBFAEB","doi-asserted-by":"crossref","unstructured":"McDougle CJ, Kresch LE, Posey DJ: Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. J Autism Dev Disord 2000; 30:425\u2013433","DOI":"10.1023\/A:1005551523657"},{"key":"R1626BABDIEHD","doi-asserted-by":"crossref","unstructured":"Campbell M, Anderson L, Meier M, Cohen I, Small A, Samit C, Sachar E: A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Psychiatry 1978; 17:640\u2013655","DOI":"10.1016\/S0002-7138(09)61017-7"},{"key":"R1626BABHBGCG","doi-asserted-by":"crossref","unstructured":"Aman MG: Recent studies in psychopharmacology in mental retardation. Int Rev Res Ment Retard 1997; 21:113\u2013146","DOI":"10.1016\/S0074-7750(08)60278-5"},{"key":"R1626BABJGAEC","doi-asserted-by":"crossref","unstructured":"McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH: Haloperidol addition in fluvoxamine-refractory obsessive compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994; 51:302\u2013308","DOI":"10.1001\/archpsyc.1994.03950040046006"},{"key":"R1626BABJJFBF","doi-asserted-by":"crossref","unstructured":"McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH: A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000; 57:794\u2013801","DOI":"10.1001\/archpsyc.57.8.794"},{"key":"R1626BABGAFJF","doi-asserted-by":"crossref","unstructured":"Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumer JL: A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 2000; 39:509\u2013516","DOI":"10.1097\/00004583-200004000-00021"},{"key":"R1626BABEHJDA","doi-asserted-by":"crossref","unstructured":"Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL (Risperidone Disruptive Behavior Study Group): Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002; 159:1337\u20131346","DOI":"10.1176\/appi.ajp.159.8.1337"},{"key":"R1626BABEHFFE","doi-asserted-by":"crossref","unstructured":"Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A (Risperidone Conduct Study Group): Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 2002; 41:1026\u20131036","DOI":"10.1097\/00004583-200209000-00002"}],"container-title":["American Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ajp.162.6.1142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T13:43:17Z","timestamp":1722174197000},"score":1,"resource":{"primary":{"URL":"https:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ajp.162.6.1142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,1]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,6,1]]}},"alternative-id":["10.1176\/appi.ajp.162.6.1142"],"URL":"https:\/\/doi.org\/10.1176\/appi.ajp.162.6.1142","relation":{},"ISSN":["0002-953X","1535-7228"],"issn-type":[{"value":"0002-953X","type":"print"},{"value":"1535-7228","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6,1]]}}}